The Role of Cereblon Pathways in Myeloma
The Role of Cereblon Pathways in Myeloma
批准号:
8669613
负责人:
SHAJI Kunnathu KUMAR
金额:
$49.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-03-31
关键词:
BindingBinding ProteinsBiologyBlindedBone MarrowBortezomibCell LineCellsClinicClinicalClinical ResearchClinical TrialsDataDevelopmentDexamethasoneDrug resistanceEnrollmentFrequenciesFutureGene ExpressionGene MutationGene ProteinsGenesGenomeGenomicsGoalsHematologic NeoplasmsImmuneImmune systemInterferon Regulatory Factor 4Malignant NeoplasmsMediatingMolecularMultiple MyelomaMutationNewly DiagnosedOutcomeParaffinPathologistPathway interactionsPatientsPharmaceutical PreparationsProteinsProteomicsRNA InterferenceRNA SequencesRefractoryRelapseResistanceRoleSalesSignal TransductionTestingThalidomideTherapeuticTherapeutic InterventionTissue MicroarrayValidationanalogdrug sensitivitygenome-widelenalidomidenovelnovel therapeuticsprospectivepublic health relevanceresponsescreeningtherapeutic development
中文摘要
描述(申请人提供):临床研究已证明免疫调节药物(IMids)治疗多发性骨髓瘤(MM)有显著疗效。事实上,沙利度胺及其结构类似物来那度胺和泊马度胺都是年销售额达数十亿美元的药物。然而,只有15%-30%的复发患者对单一药物有反应,而大多数对治疗有反应的患者最终会产生获得性耐药性。我们研究了沙利度胺的主要靶点雷波隆(CRBN)在IMIDS抗MM活性中的作用,证明了CRBN是沙利度胺、泊马度胺和来那度胺的抗癌和免疫活性所必需的。我们最近在高度耐药的患者中首次发现了CRBN的基因组失活突变,并证明了CRBN的基因表达水平可以预测接受IMIDS治疗的MM患者的反应和生存结果。我们和其他人确定干扰素调节因子4(IRF4)是CRBN相关信号的关键下游靶点之一,与IMiD耐药性相关。因此,CRBN-IRF4轴是开发新疗法的靶点,在血液系统恶性肿瘤和免疫系统操作中具有广泛的应用。这些发现和我们团队已经开发的临床、细胞和分子工具包为开发临床反应预测因子和识别靶标打开了大门,这些靶标不仅包括CRBN本身,还包括其下游效应物。
以克服IMIDD的抵抗力。本研究的三个目的是:1.构建635例患者组织芯片(TMA),并用定量水免疫荧光法(IF)或免疫荧光技术(IHC)验证IMiD耐药效应。2.在IMID难治性骨髓瘤的前瞻性临床试验中,我们将产生CRBN通路突变导致耐药性的频率的数据。3.我们将整合全基因组RNA干扰筛选和MS蛋白质组学,以确定CRBN下游的新靶点,作为未来治疗学发展的潜在切入点。
英文摘要
DESCRIPTION (provided by applicant): Clinical studies have demonstrated the remarkable efficacy of immunomodulatory drugs (IMiDs) for the treatment of Multiple Myeloma (MM). Indeed, Thalidomide and its structural analogs Lenalidomide and Pomalidomide are drugs with billions of dollars in sales annually. However only 15-30% of relapsed patients respond to single agent drug and a majority of those patients who respond to treatment eventually develop acquired drug resistance. We have investigated the functional role of cereblon (CRBN), a primary target of Thalidomide, in the anti-MM activity of IMiDs and demonstrated that CRBN is absolutely required for the anti- cancer and immune activity of Thalidomide, Pomalidomide and Lenalidomide. We recently identified the first genomic inactivating mutations in CRBN in highly drug resistant patients and have demonstrated that gene expression levels of CRBN can predict response and survival outcomes in MM patients receiving IMiDs. We and others identified interferon regulatory factor 4 (IRF4) as one of the key downstream targets of CRBN-associated signaling, associated with IMiD drug resistance. Thus the CRBN-IRF4 axis is a target for development of new therapeutics with broad application in hematologic malignancies and immune system manipulation. These findings and the clinical, cellular and molecular toolkits already developed by our team open the door to development of clinical predictors of response and the identification of targets including not only CRBN itself, but also its downstream effectors
to overcome IMiD resistance. The three aims of this study are: 1. We will construct a 635 patient tissue microarray (TMA) and use quantitative AQUA immunoflourescence (IF) or IHC to validate effectors of IMiD drug resistance. 2. In a prospective clinical trial in IMiD refractory Myeloma we will generate data on the frequency of CRBN pathway mutation contributing to drug resistance. 3. We will integrate genome wide RNA interference screening and MS proteomics to identify novel targets downstream of CRBN as potential entry points in the future development of therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Cereblon Pathways in Myeloma
-
批准号:9024349
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2014
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8342326
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8512677
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10206030
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10656463
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8846552
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10471179
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Prevalence and Progression of Monoclonal Gammopathies
-
批准号:9015415
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Prevalence and Progression of Monoclonal Gammopathies
-
批准号:8692316
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10362661
-
项目类别:
-
资助金额:$55.8万
-
财政年份:1997
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10113628
-
项目类别:
-
资助金额:$55.79万
-
财政年份:1997
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
海外基金